Research Overview
What the missing tripeptide does
The N-terminal Gly-Pro-Glu of IGF-1 contributes disproportionately to binding protein recognition, with the glutamate at position 3 forming a key interaction. Removing all three residues has been reported to reduce IGFBP affinity by one to two orders of magnitude while leaving the IGF-1 receptor binding surface essentially intact. The result is an analogue whose measured potency in serum-containing assays can far exceed that of native IGF-1 — not because receptor affinity improved, but because less of it is sequestered.
A naturally occurring variant
DES(1-3) was originally purified from bovine colostrum and from human brain extracts, and is thought to arise from proteolytic processing of intact IGF-1 in tissue. Its released Gly-Pro-Glu tripeptide has itself been a subject of separate neuropeptide research, which is why the analogue occasionally appears in neuroscience literature as well as growth factor work.
Experimental applications
- Myoblast and satellite cell cultures examining proliferation, differentiation and hypertrophy signalling through PI3K–Akt and MAPK pathways
- Assays designed to isolate receptor-level effects from binding-protein modulation, using DES(1-3) as the binding-protein-independent comparator
- Side-by-side potency comparison with IGF-1 LR3 and native IGF-1 in matched media conditions
Practical differences from LR3
Because it is smaller and lacks the stabilising N-terminal extension of LR3, DES(1-3) is generally described as having a shorter functional window in culture and in animal models. Investigators choose it when a short, sharp receptor stimulus is wanted and LR3 when sustained exposure is. All of this describes laboratory research only. Analytically, the two analogues are also distinguished by mass: at roughly 7371 versus 9118 g/mol they resolve cleanly by mass spectrometry and by size-based separation, which makes mixed-standard method development straightforward when both are used in the same experimental programme.
